Walgreens kicks off flu prevention campaign with ‘The Dr. Oz Show’
DEERFIELD, Ill. Walgreens has teamed up with “The Dr. Oz Show” to educate the public about the importance of flu prevention.
“The Dr. Oz Show” host, Dr. Mehmet Oz, will answer questions regarding the upcoming flu season and the importance of flu prevention. Walgreens, which offers flu shots at all of its pharmacies and Take Care Clinics nationwide, is partnering with “The Dr. Oz Show” in conjunction with one of the most comprehensive flu shot programs in the nation. The partnership includes a number of elements and media integrations.
Additionally, Walgreens pharmacist Stacia Woodcock will appear on the Sept. 21 episode of “The Dr. Oz Show” to discuss the latest information regarding the 2010-2011 flu season, and will administer a flu shot to Dr. Oz during the show.
“We’re proud to again work with ‘The Dr. Oz Show’ to keep America healthy throughout what’s always an unpredictable flu season,” said Kim Feil, Walgreens chief marketing officer. “We have shared goals of encouraging people to be proactive when it comes to flu prevention and overall preventative health, and together we look forward to providing the resources for people to stay well.”
House committee to hold hearing over J&J recall
WASHINGTON House Committee on Oversight and Government Reform chairman Ed Towns, D-N.Y., on Thursday announced that the committee will hold a hearing Sept. 30 at 10 a.m. to examine the circumstances surrounding Johnson & Johnson’s recall of more than 135 million bottles of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare, including children’s Tylenol, infant’s Tylenol, children’s Motrin and children’s Benadryl.
The hearing also will examine the circumstances surrounding a “phantom recall” of a particular Motrin product, which became public as a result of the committee’s hearing on May 27.
“This is about the safety of trusted medication that our children and grandchildren use,” Towns stated. “The evidence we have uncovered since our first hearing is extremely troubling.”
Witnesses invited to testify include Bill Weldon, J&J chairman and CEO, and Colleen Goggins, J&J worldwide chairman, consumer group.
The hearing will be webcast on the committee’s website, Oversight.house.gov.
Forest Pharmaceuticals pays $313 million in settlement deal
SILVER SPRING, Md. Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as part of a plea agreement over alleged improper drug distribution and obstructing a Food and Drug Administration inspection.
The FDA said Wednesday that Forest Pharmaceuticals, a subsidiary of New York-based Forest Labs, had entered a plea agreement whereby it would accept criminal responsibility for distribution of an unapproved drug, distribution of a misbranded drug and obstruction of an FDA inspection. The total payment of $313 million includes $164 million in criminal penalties.
One charge centered around the marketing of Levothroid (levothyroxine sodium), an unapproved drug used to treat hypothyroidism. A 1997 Federal Register notice announced that Levothroid is a “new drug,” and that manufacturers who wish to continue marketing it would have to obtain approval from the FDA by August 2000.
The company also is charged with alleged off-label promotion of the antidepressant Celexa (citalopram) for use in children; the drug is only approved for use in adults. The charge of obstructing an FDA inspection relates to an alleged 2003 incident in which Forest employees made false statements to the agency.
“We are pleased to bring closure to this long-running investigation,” Forest chairman and CEO Howard Solomon said. “We remain dedicated to ensuring that we operate in full compliance with all laws and regulations and that our employees uphold the highest principles of integrity, honesty and ethics.”